Fosigotifator by Calico Life Sciences for Unspecified Central Nervous System Disorders: Likelihood of Approval

Fosigotifator is under clinical development by Calico Life Sciences and currently in Phase II for Unspecified Central Nervous System Disorders.

RA Capital and Forbion set up new autoimmune biotech with bispecific from Korean startup

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

August 28, 2024

New study highlights impact of COVID-19 pandemic on emergency department visits in British Columbia

A new study showing the impact of the COVID-19 pandemic and mitigation strategies used to manage the virus on emergency department (ED) visits in British

September 5, 2023

One Copeptin Test More Accurate as Diagnostic for AVP Deficiency

Arginine-stimulated copeptin was inferior to hypertonic saline-stimulated copeptin in the diagnosis of arginine vasopressin (AVP) deficiency, formerly known as central diabetes insipidus, the CARGOx trial

November 16, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.